These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 21651347)

  • 1. Linaclotide, a synthetic guanylate cyclase C agonist, for the treatment of functional gastrointestinal disorders associated with constipation.
    Vazquez Roque M; Camilleri M
    Expert Rev Gastroenterol Hepatol; 2011 Jun; 5(3):301-10. PubMed ID: 21651347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review of the clinical efficacy of linaclotide in irritable bowel syndrome with constipation.
    Johnston JM; Shiff SJ; Quigley EM
    Curr Med Res Opin; 2013 Feb; 29(2):149-60. PubMed ID: 23198977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging receptor target in the pharmacotherapy of irritable bowel syndrome with constipation.
    Blackshaw LA; Brierley SM
    Expert Rev Gastroenterol Hepatol; 2013 Jul; 7(5 Suppl 1):15-9. PubMed ID: 23859756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Linaclotide, novel therapy for the treatment of chronic idiopathic constipation and constipation-predominant irritable bowel syndrome.
    Vazquez-Roque MI; Bouras EP
    Adv Ther; 2013 Mar; 30(3):203-11. PubMed ID: 23436110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit.
    Busby RW; Bryant AP; Bartolini WP; Cordero EA; Hannig G; Kessler MM; Mahajan-Miklos S; Pierce CM; Solinga RM; Sun LJ; Tobin JV; Kurtz CB; Currie MG
    Eur J Pharmacol; 2010 Dec; 649(1-3):328-35. PubMed ID: 20863829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome.
    Andresen V; Camilleri M; Busciglio IA; Grudell A; Burton D; McKinzie S; Foxx-Orenstein A; Kurtz CB; Sharma V; Johnston JM; Currie MG; Zinsmeister AR
    Gastroenterology; 2007 Sep; 133(3):761-8. PubMed ID: 17854590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of novel promotility and prosecretory agents for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation.
    Gale JD
    Adv Ther; 2009 May; 26(5):519-30. PubMed ID: 19444393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current and emerging treatments for irritable bowel syndrome with constipation and chronic idiopathic constipation: focus on prosecretory agents.
    Thomas RH; Luthin DR
    Pharmacotherapy; 2015 Jun; 35(6):613-30. PubMed ID: 26016701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Constella™(EU)-Linzess™(USA): the last milestone in the long journey of the peptide linaclotide and its implications for the future of peptide drugs.
    Góngora-Benítez M; Tulla-Puche J; Albericio F
    Future Med Chem; 2013 Mar; 5(3):291-300. PubMed ID: 23464519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Linaclotide for treatment of irritable bowel syndrome--the view of European regulators.
    Berntgen M; Enzmann H; Schabel E; Prieto Yerro C; Gómez-Outes A; Salmonson T; Musaus J
    Dig Liver Dis; 2013 Sep; 45(9):724-6. PubMed ID: 23701993
    [No Abstract]   [Full Text] [Related]  

  • 11. The pharmacokinetics, pharmacodynamics, clinical efficacy, safety and tolerability of linaclotide.
    Lee N; Wald A
    Expert Opin Drug Metab Toxicol; 2011 May; 7(5):651-9. PubMed ID: 21446888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Linaclotide: a novel compound for the treatment of irritable bowel syndrome with constipation.
    Rothstein RD; Friedenberg FK
    Expert Opin Pharmacother; 2013 Oct; 14(15):2125-32. PubMed ID: 24007408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clarification of trial end points presented in a recent review of linaclotide.
    Johnston JM; Schneier HA
    Expert Rev Gastroenterol Hepatol; 2012 Feb; 6(1):13-4; author reply 15. PubMed ID: 22149576
    [No Abstract]   [Full Text] [Related]  

  • 14. How can we achieve relief of bowel and abdominal symptoms for patients with irritable bowel syndrome with constipation?
    Tack J
    Expert Rev Gastroenterol Hepatol; 2013 Jul; 7(5 Suppl 1):21-6. PubMed ID: 23859757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Linaclotide: a novel agent for chronic constipation and irritable bowel syndrome.
    Love BL; Johnson A; Smith LS
    Am J Health Syst Pharm; 2014 Jul; 71(13):1081-91. PubMed ID: 24939497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation.
    Johnston JM; Kurtz CB; Macdougall JE; Lavins BJ; Currie MG; Fitch DA; O'Dea C; Baird M; Lembo AJ
    Gastroenterology; 2010 Dec; 139(6):1877-1886.e2. PubMed ID: 20801122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pilot study on the effect of linaclotide in patients with chronic constipation.
    Johnston JM; Kurtz CB; Drossman DA; Lembo AJ; Jeglinski BI; MacDougall JE; Antonelli SM; Currie MG
    Am J Gastroenterol; 2009 Jan; 104(1):125-32. PubMed ID: 19098860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Linaclotide: first global approval.
    McWilliams V; Whiteside G; McKeage K
    Drugs; 2012 Nov; 72(16):2167-75. PubMed ID: 23083112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomised clinical trials: linaclotide phase 3 studies in IBS-C - a prespecified further analysis based on European Medicines Agency-specified endpoints.
    Quigley EM; Tack J; Chey WD; Rao SS; Fortea J; Falques M; Diaz C; Shiff SJ; Currie MG; Johnston JM
    Aliment Pharmacol Ther; 2013 Jan; 37(1):49-61. PubMed ID: 23116208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two randomized trials of linaclotide for chronic constipation.
    Lembo AJ; Schneier HA; Shiff SJ; Kurtz CB; MacDougall JE; Jia XD; Shao JZ; Lavins BJ; Currie MG; Fitch DA; Jeglinski BI; Eng P; Fox SM; Johnston JM
    N Engl J Med; 2011 Aug; 365(6):527-36. PubMed ID: 21830967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.